PARITAPREVIR

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category Free-form
UNII OU2YM37K86

Structure

InChI Key UAUIUKWPKRJZJV-QPLHLKROSA-N
Smiles Cc1cnc(C(=O)N[C@H]2CCCCC/C=C\[C@@H]3C[C@@]3(C(=O)NS(=O)(=O)C3CC3)NC(=O)[C@@H]3C[C@@H](Oc4nc5ccccc5c5ccccc45)CN3C2=O)cn1
InChI
InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C40H43N7O7S
Molecular Weight 765.89
AlogP 3.64
Hydrogen Bond Acceptor 10.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 7.0
Polar Surface Area 189.65
Molecular species ACID
Aromatic Rings 4.0
Heavy Atoms 55.0

Bioactivity

Mechanism of Action Action Reference
Hepatitis C virus serine protease, NS3/NS4A inhibitor INHIBITOR FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Protease Serine protease Serine protease PA clan Serine protease S29 family Serine protease S29 regulatory subfamily
- - - - 97
Enzyme Protease Serine protease Serine protease PA clan Serine protease S29 family
- - - - 97
Assay Description Organism Bioactivity Reference
Antiviral activity against HCV genotype 1b after 3 days by luciferase reporter assay Hepatitis C virus subtype 1b 0.21 nM
Inhibition of HCV NS3/4A protease Hepatitis C virus 0.18 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 0.28 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 8.55 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 14.05 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.17 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.01 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.17 %
Inhibition of HCV NS3/4a protease Hepatitis C virus 97.0 %

Cross References

Resources Reference
ChEMBL CHEMBL3391662
DrugBank DB09297
DrugCentral 4913
FDA SRS OU2YM37K86
Guide to Pharmacology 11273
PharmGKB PA166163410
PubChem 45110509
SureChEMBL SCHEMBL3069964
ZINC ZINC000197964623
CONTENTS